News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
702,664 Results
Type
Article (41075)
Company Profile (256)
Press Release (661333)
Multimedia
Podcasts (47)
Webinars (12)
Section
Business (205355)
Career Advice (2064)
Deals (35584)
Drug Delivery (96)
Drug Development (81198)
Employer Resources (174)
FDA (16228)
Job Trends (14995)
News (346915)
Policy (32738)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (8)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2634)
Accelerated approval (5)
Adcomms (20)
Allergies (82)
Alliances (49816)
ALS (87)
Alzheimer's disease (1376)
Antibody-drug conjugate (ADC) (112)
Approvals (16229)
Artificial intelligence (250)
Autoimmune disease (21)
Automation (15)
Bankruptcy (363)
Best Places to Work (11693)
BIOSECURE Act (18)
Biosimilars (104)
Biotechnology (179)
Bladder cancer (62)
Brain cancer (26)
Breast cancer (266)
Cancer (2099)
Cardiovascular disease (167)
Career advice (1726)
Career pathing (29)
CAR-T (143)
Cell therapy (405)
Cervical cancer (19)
Clinical research (65916)
Collaboration (802)
Compensation (515)
Complete response letters (19)
COVID-19 (2615)
CRISPR (37)
C-suite (226)
Cystic fibrosis (100)
Data (2059)
Decentralized trials (2)
Denatured (17)
Depression (40)
Diabetes (258)
Diagnostics (6464)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (96)
Drug shortages (25)
Duchenne muscular dystrophy (91)
Earnings (86517)
Editorial (35)
Employer branding (22)
Employer resources (148)
Events (112476)
Executive appointments (701)
FDA (17422)
Featured Employer (49)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (724)
Gene editing (100)
Generative AI (21)
Gene therapy (287)
GLP-1 (706)
Government (4438)
Grass and pollen (4)
Guidances (51)
Healthcare (18915)
Huntington's disease (23)
IgA nephropathy (24)
Immunology and inflammation (111)
Indications (27)
Infectious disease (2756)
Inflammatory bowel disease (133)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (91)
Interviews (317)
IPO (16535)
IRA (40)
Job creations (3715)
Job search strategy (1471)
Kidney cancer (9)
Labor market (36)
Layoffs (467)
Leadership (18)
Legal (7952)
Liver cancer (72)
Lung cancer (302)
Lymphoma (139)
Machine learning (5)
Management (58)
Manufacturing (285)
MASH (62)
Medical device (13425)
Medtech (13430)
Mergers & acquisitions (19569)
Metabolic disorders (659)
Multiple sclerosis (75)
NASH (16)
Neurodegenerative disease (83)
Neuropsychiatric disorders (24)
Neuroscience (1885)
NextGen: Class of 2025 (6577)
Non-profit (4524)
Northern California (2543)
Now hiring (38)
Obesity (355)
Opinion (209)
Ovarian cancer (73)
Pain (80)
Pancreatic cancer (80)
Parkinson's disease (148)
Partnered (21)
Patents (222)
Patient recruitment (99)
Peanut (46)
People (57607)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20531)
Phase II (29028)
Phase III (21631)
Pipeline (1116)
Policy (130)
Postmarket research (2569)
Preclinical (8720)
Press Release (68)
Prostate cancer (99)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (372)
Real estate (6049)
Recruiting (66)
Regulatory (22350)
Reports (46)
Research institute (2394)
Resumes & cover letters (353)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (65)
Series A (127)
Series B (81)
Service/supplier (13)
Sickle cell disease (52)
Southern California (2194)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3627)
State (2)
Stomach cancer (13)
Supply chain (66)
Tariffs (26)
The Weekly (28)
United States (22160)
Vaccines (671)
Venture capitalists (38)
Weight loss (229)
Women's health (34)
Worklife (16)
Date
Today (85)
Last 7 days (444)
Last 30 days (2246)
Last 365 days (33013)
2025 (9333)
2024 (35366)
2023 (40252)
2022 (51416)
2021 (55934)
2020 (54410)
2019 (46899)
2018 (35247)
2017 (32447)
2016 (31873)
2015 (37854)
2014 (31618)
2013 (26710)
2012 (28894)
2011 (29577)
2010 (27546)
Location
Africa (740)
Alabama (52)
Alaska (7)
Arizona (231)
Arkansas (13)
Asia (38198)
Australia (6230)
California (5815)
Canada (1951)
China (496)
Colorado (256)
Connecticut (262)
Delaware (136)
Europe (81878)
Florida (863)
Georgia (208)
Idaho (58)
Illinois (514)
India (25)
Indiana (303)
Iowa (10)
Japan (150)
Kansas (102)
Kentucky (23)
Louisiana (9)
Maine (62)
Maryland (862)
Massachusetts (4354)
Michigan (215)
Minnesota (381)
Mississippi (2)
Missouri (79)
Montana (27)
Nebraska (25)
Nevada (60)
New Hampshire (63)
New Jersey (1674)
New Mexico (29)
New York (1671)
North Carolina (943)
North Dakota (7)
Northern California (2543)
Ohio (201)
Oklahoma (14)
Oregon (33)
Pennsylvania (1306)
Puerto Rico (11)
Rhode Island (31)
South America (1120)
South Carolina (20)
South Dakota (1)
Southern California (2194)
Tennessee (99)
Texas (867)
Utah (176)
Virginia (138)
Washington D.C. (59)
Washington State (533)
West Virginia (3)
Wisconsin (51)
702,664 Results for "geovax labs inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Vaccines
HHS Pulls Funding for GeoVax’s Next-Gen COVID-19 Vaccine
GeoVax was using its HHS contract to develop its next-generation multi-antigen COVID-19 vaccine, which is in Phase IIb development.
April 17, 2025
·
2 min read
·
Tristan Manalac
Policy
GeoVax Announces Multiple Patent Issuances and Allowances
GeoVax Labs, Inc. announced multiple actions by global patent offices strengthening the Company’s intellectual property assets.
February 13, 2024
·
5 min read
Press Releases
Registration is Now Open for Tribe Public’s Webinar Event “Now Is Not the Time to Monkey(pox) Around” Featuring GeoVax Lab’s CEO
August 22, 2024
·
3 min read
BioMidwest
Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023
GeoVax Labs, Inc. announced the presentation of preclinical vaccine efficacy data for GEO-CM02, a multi-antigen investigational SARS-CoV-2 vaccine.
November 14, 2023
·
7 min read
BioMidwest
GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities
GeoVax Labs, Inc., a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced an update on key strategic initiatives.
October 24, 2023
·
6 min read
BioMidwest
GeoVax to Participate in Upcoming November 2023 Investor and Industry Events
GeoVax Labs, Inc. announced that members of its senior management team and other scientific representatives will participate in four upcoming investor and industry events during November.
October 25, 2023
·
3 min read
Press Releases
ProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024
April 1, 2025
·
21 min read
Drug Development
GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the closure of patient enrollment for the Phase 1/2 clinical study evaluating Gedeptin® in patients suffering from advanced head and neck cancer.
January 4, 2024
·
7 min read
Press Releases
ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025
March 28, 2025
·
1 min read
GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will participate in the Alliance Global Partners’ Virtual Healthcare Conference being held May 23-24, 2023.
May 9, 2023
·
1 min read
1 of 70,267
Next
